Indrayani Biotech Intrinsic Value
Indrayani Biotech (INDRANIB) median intrinsic value is ₹15.68 from 8 valuation models (range ₹2–₹20), vs current price ₹7.84 — +100.0% upside (Trading Below Calculated Value), margin of safety 50.0%. Analyse Indrayani Biotech ownership structure to track promoter, FII and institutional holdings.
INDRANIB Valuation Methods Summary — DCF, Graham Number & P/E
Indrayani Biotech intrinsic value across 8 models vs current price ₹7.84 — upside/downside and value range per method. Read INDRANIB dividend yield for the complete payout history and dividend yield track record.
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| P/E Based Valuation | earnings | ₹4.32 | ₹3.46 - ₹5.18 | -44.9% | EPS: ₹0.36, Sector P/E: 12x |
| Book Value Method | asset | ₹19.60 | ₹17.64 - ₹21.56 | +150.0% | Book Value/Share: ₹21.74, P/B: 1.0x |
| Revenue Multiple Method | revenue | ₹15.68 | ₹14.11 - ₹17.25 | +100.0% | Revenue/Share: ₹33.04, P/S: 0.8x |
| EBITDA Multiple Method | earnings | ₹15.68 | ₹14.11 - ₹17.25 | +100.0% | EBITDA: ₹16.00Cr, EV/EBITDA: 6x |
| Simple DCF (5Y) | dcf | ₹19.60 | ₹15.68 - ₹23.52 | +150.0% | CF Growth: 15.0%, Discount: 15% |
| PEG Ratio Method | growth | ₹2.35 | ₹2.12 - ₹2.59 | -70.0% | EPS Growth: 8.0%, Fair P/E: 6.4x |
| Growth Adjusted P/E | growth | ₹2.97 | ₹2.67 - ₹3.27 | -62.1% | Revenue Growth: 6.0%, Adj P/E: 8.2x |
| Graham Defensive Method | conservative | ₹13.27 | ₹11.94 - ₹14.60 | +69.3% | EPS: ₹0.36, BVPS: ₹21.74 |
INDRANIB Intrinsic Value vs Market Price — All Valuation Models
Indrayani Biotech fair value range ₹2–₹20 vs current market price ₹7.84 across 8 valuation models. For current market price and key ratios, visit INDRANIB share price screener.
INDRANIB Intrinsic Value Analysis — Undervalued or Overvalued?
Indrayani Biotech median intrinsic value ₹15.68, current price ₹7.84 — Trading Below Calculated Value by 100.0%, margin of safety 50.0%.
What is the intrinsic value of INDRANIB?
Based on our comprehensive analysis using 8 different valuation methods, the estimated intrinsic value of Indrayani Biotech (INDRANIB) is ₹15.68 (median value). With the current market price of ₹7.84, this represents a +100.0% variance from our estimated fair value.
The valuation range spans from ₹2.35 to ₹19.60, indicating ₹2.35 - ₹19.60.
Is INDRANIB undervalued or overvalued?
Based on our multi-method analysis, Indrayani Biotech (INDRANIB) appears to be trading below calculated value by approximately 100.0%.
INDRANIB Financial Health — Key Ratios vs Industry Benchmarks
Indrayani Biotech financial ratios — ROE, debt-to-equity, profit margins and liquidity vs industry benchmarks and their impact on intrinsic value.
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Current Ratio | 2.70 | Industry Standard: 2.0+ | Above 2.0 | Measures short-term liquidity capacity |
| Return on Equity | 4.0% | Industry Standard: 15%+ | Below 10% | Measures shareholder return efficiency |
| Operating Margin | 7.0% | Industry Standard: 20%+ | Below 10% | Indicates operational efficiency level |
| Asset Turnover Ratio | 0.57x | Industry Standard: 1.0x+ | Above 0.5x | Measures asset utilization efficiency |
INDRANIB Cash Flow Quality — Operating & Free Cash Flow
Indrayani Biotech operating cash flow, free cash flow, quality rating and sustainability score by period — key inputs to DCF intrinsic value calculation.
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2025 | ₹-7 Cr | ₹-7 Cr | Negative Cash Flow | 3/10 |
| March 2024 | ₹-30 Cr | ₹-38 Cr | Negative Cash Flow | 3/10 |
| March 2023 | ₹16 Cr | ₹-8 Cr | Positive Operating Cash Flow | 6/10 |
| March 2022 | ₹4 Cr | ₹4 Cr | Positive Free Cash Flow | 8/10 |
| March 2021 | ₹0 Cr | ₹-1 Cr | Negative Cash Flow | 3/10 |